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ABSTRACT 
 
The current study compared the physicochemical properties of 7 Acetaminophen (AAP) formulations from 
Thailand (3 formulations), the Philippines (3 formulations), and Japan (1 formulation). This study assessed the 
appearance of formulations from Thailand (T-A, -B, and -C), the Philippines (P-A, -B, and -C), and Japan (J). 
This study was subjected to a hardness test, uniformity of weight test, content uniformity test, and dissolution 
test in accordance with the Japanese Pharmacopoeia. Results of the hardness test indicated that all of the 
formulations had a hardness of 70 N or greater. All formulations showed within 97–02% by uniformity of 
weight test. Comparison of dissolution profiles indicated that the P-B formulation had dissolution of about 77% 
at 15 min, and this level of elution was lower than that from other formulations (p<0.05). Unlike the P-B 
formulation, the other 6 formulations had around 85% or more elution of AAP in 15 min. The physical and 
chemical properties of the T-A, -B and -C formulations that are used in the Thailand, the P-A and -C 
formulations that are used in the Philippines, and the J formulation that is used in Japan complied with the 
Japanese Pharmacopoeia. Thus, these formulations are assumed to be equivalent. 
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INTRODUCTION 
 
Acetaminophen (N-acetyl-p-aminophenol: AAP 
(paracetamol)) is a drug that has been widely used 
in clinical practice as an antipyretic/analgesic. Use 
of non-steroidal anti-inflammatory drugs (NSAIDs) 
like aspirin in children is avoided over concerns 
about exacerbating influenza-associated 
encephalopathy. This is why AAP is commonly 
used as an antipyretic/analgesic for children. AAP 
and NSAIDs are non-opioid analgesics. The 3-step 
analgesic ladder of the World Health Organization 
(WHO) describes drugs to manage cancer pain, and 
the first step in that ladder is the use of AAP or an 
NSAID1-2. AAP is considered useful in various 
situations, but poisoning due to an overdose poses a 
problem. AAP can cause several problems, 
including elevated methemoglobin resulting in 
cyanosis, hemolysis resulting in anemia, renal 
dysfunction, and hepatic dysfunction3-4. Therefore, 
pharmaceutical equivalence is an important factor 
in terms of therapeutic effectiveness and safety. A 
dissolution test is commonly conducted in vitro in 
order to ensure the pharmaceutical equivalence of 
orally administered tablets and capsules. This is 
because there are differences between batches, and 
such testing facilitates the development of different 
dosage forms and it helps to ensure the quality of 
preparations. Predicting a preparation’s 
bioequivalence and bioavailability in vitro is also 
crucial5-6. 
 
Over the past few years, an increasing number of 
countries allow AAP to be purchased without a 
prescription. In the Philippines, for example, 
customers can purchase AAP as an antipyretic once 
they explain their symptoms to a pharmacist at the 
counter of a pharmacy. In Thailand, AAP can be 
purchased at convenience stores in town. Although 
AAP must be purchased with an understanding of 
the effectiveness, efficacy, and safety of 
paracetamol and the characteristics of the 
preparation in question, information on the 
characteristics of that preparation may not be 
conveyed to the patient. In contrast, AAP is still a 
prescription drug in Japan. A patient may obtain 
AAP from a pharmacist pursuant to a prescription 
from his or her doctor. In February 2015, a 500-mg 
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AAP formulation became available by prescription 
in Japan. This formulation, which is manufactured 
in accordance with the Japanese Pharmacopoeia, 
adheres to the same standards as formulations 
available overseas.  
  
In the current study, the Japanese 500-mg AAP 
formulation was used as a reference standard to 
assess the physicochemical properties of 6 other 
formulations, 3 of which came from Thailand and 3 
of which came from the Philippines. The 
appearance of the formulations and blister packs 
were assessed, and a hardness test and a uniformity 
of weight test were conducted to verify the 
properties of each formulation. As described here, a 
content uniformity test and a dissolution test were 
also conducted to assess the quality of the 
formulations. 
 
MATERIALS AND METHODS  
 
Materials: Seven different AAP formulations were 
used in the present study. Three AAP formulations 
of 500-mg caplets were from Thailand: Paracap 
from Masa Lab Co. Ltd. (Lot No. 140320) was 
designated T-A, SaRa from Thai Nakorn Patana 
(Lot No. 0140414) was designated T-B, and 
Tylenol from Janssen-Cilag Ltd. (Lot No. 401245) 
was designated T-C. Three AAP formulations of 
500-mg tablets were from the Philippines: 
Biogestic from United Lab (14038301) was 
designated P-A, Rapidol from Pasteur Pharma (Lot 
No. BC141M04) was designated P-B, and 
Paracetamol from JB Orchid Pharmaceuticals, Inc. 
(9634) was designated P-C. One formulation of 
500-mg caplets was from Japan: Calonal from 
Showa Yakuhin Kako Co., Ltd. (Lot No. 4041V) 
was designated J (Table 1). In addition, a standard 
sample of AAP and other reagents were purchased 
from Wako Pure Chemical Industries Ltd., Japan. 
 
Determination of appearance: Formulations were 
uncoated tablets or caplets. The diameter of the 
caplet/tablet was measured and stamping on its 
surface was noted. Labeling on the formulation’s 
blister pack was also noted. 
 
Hardness test: The hardness of 10 tablets/caplets 
of each formulation was measured in the direction 
of the diameter using a Monsanto tablet hardness 
tester (Minato Medical Co., Ltd.). 
 
Uniformity of weight test: A uniformity of weight 
test was conducted with each formulation. The 
weight of 10 uncoated tablets/caplets was measured 
using an electronic balance (AUW220D, 
Shimadzu, Tokyo). 
 
Disintegration test: A disintegration test was 
conducted with a disintegration tester (NT-2H, 
Toyama Sangyo) to measure the disintegration time 
for 5 tablets/caplets of each formulation. 
 
Content uniformity test: A content uniformity test 
was conducted in accordance with the 16th edition 
of the Japanese Pharmacopoeia. A sample solution 
was prepared using 10 tablets/caplets of each 
formulation and a standard solution was prepared 
using a standard sample of AAP. For the standard 
solution, each tablet/caplet was placed in a 200-mL 
water:methanol (25:25) solution, and the solution 
was shaken for 60 min. After shaking, 10 mL of the 
sample solution was collected and filtered using a 
0.2-μm membrane filter. Five mL of the filtrate was 
diluted to 50 mL with water:methanol (25:25). 
Afterwards, 5 mL of that sample solution was 
measured and diluted to 50 mL with 
water:methanol (25:25). Five mL of that sample 
solution was measured and diluted to 50 mL with 
water:methanol (25:25) to obtain the sample 
solution. High-performance liquid chromatography 
(HPLC) was used to calculate the AAP content in 
proportion to the indicated amount of AAP in the 
formulation. Content was ascertained by 
determining the acceptance value in accordance 
with the 16th edition of the Japanese 
Pharmacopoeia. The criterion for the acceptance 
value is 16% according to the Japanese 
Pharmacopeia. If the acceptance value did not 
exceed 15%, the formulation complied with the 
Japanese Pharmacopeia.  
 
Dissolution test: A dissolution test was conducted 
in accordance with the paddle method in the 16th 
edition of the Japanese Pharmacopoeia and the 
Guidelines for Bioequivalence Testing of Generic 
Drugs12 (hereafter denoted as the Guidelines). 
Dissolution testing of samples was performed using 
a dissolution apparatus (NTR-593, Toyama 
Sangyo) at 37 ± 0.5°C with 900 mL of distilled 
water that was stirred at 50 rpm using the paddle 
method. Ten mL of each sample solution was 
collected after 0, 5, 10, 15, 30, and 60 min and then 
filtered through a 0.20-µm membrane ﬁlter. 
Afterwards, 5 mL of the ﬁltered sample was 
measured and diluted to 50 mL with 
water:methanol (20:25). Five mL of the diluted 
sample solution was diluted to 50 mL with 
water:methanol (25:25) to serve as the sample 
solution. The AAP content in each sample solution 
was determined using HPLC. 
 
HPLC: HPLC was performed in accordance with a 
dissolution test for AAP tablets as specified in the 
3rd section of the Japanese Pharmaceutical Codex 
(denoted here as the 3rd section of the JPC). Assays 
were done with a high-performance liquid 
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chromatograph (HPLC, SPD-20A Shimadzu, 
Kyoto). Assay conditions were a column of Inertsil 
ODS-3 (4.6×150 mm, 5 μm), a column temperature 
of 40°, a mobile phase consisting of a mixture of 
0.05 mol/l potassium dihydrogen phosphate and 
methanol (4:1, pH 4.7), and a detection wavelength 
of 245 nm. AAP retention time was set so that the 
flow rate would be 5 min, and the sample injection 
volume was 40 µL. 
 
Statistical analysis: Results are presented as the 
mean ± standard deviation, and statistical 
significance was evaluated using the Tukey-
Kramer test. 
 
RESULTS 
 
Hardness test: Results of the hardness test were 
148.0±10.2 N for the T-A formulation, 137.0±13.2 
N for the T-B formulation, 106.5±5.5 N for the T-C 
formulation, 215.9±11.6 N for the P-A formulation, 
107.8±12.7 N for the P-B formulation, 71.5±10.6 N 
for the P-F formulation, and 91.7±2.4 N for the J 
formulation. All of the formulations had a hardness 
of 70 N or greater (Table 2). Significant differences 
between the T-A formulation and the T-B 
formulation and between the T-C formulation and 
the P-B formulation in terms of hardness were not 
noted. However, significant differences in hardness 
(p<0.05) were noted for other formulations.  
 
Uniformity of weight test: The weight of the T-A 
formulation, the T-B formulation, the P-B 
formulation, and the J formulation was around 550 
mg. However, the T-C formulation, the P-A 
formulation, and the P-C formulation had a weight 
of 600 mg or greater.  
 
Content uniformity test: Results of the uniformity 
of weight test are shown in Table 2. The AAP 
content in individual formulations ranged from 97–
102% of the labeled content. The acceptance value 
for the T-A formulation was 4.3, that for the T-B 
formulation was 8.5, that for the T-C formulation 
was 10.9, that for the P-A formulation was 5.1, that 
for the P-B formulation was 7.1, that for the P-C 
formulation was 8.9, and that for the J formulation 
was 3.9. Acceptance values for all of the 
formulations were 15% or less (the criterion in the 
16th edition of the Japanese Pharmacopoeia), so 
requirements were met.  
 
Disintegration test: Results of the disintegration 
test were 74.0±2.8 s for the T-A formulation, 
128.5±19.9 s for the T-B formulation, 144.3±10.6 s 
for the T-C formulation, 192.2±11.7 s for the P-A 
formulation, 429.3±13.8 s for the P-B formulation, 
121.8±22.9 s for the P-C formulation, and 
169.7±21.2 s for the J formulation. The 
disintegration time was 300 sec or less for all of the 
formulations except the P-B formulation (Table 2). 
Significant differences between the P-B 
formulation and the T-A formulation, the T-B 
formulation, the T-C formulation, the P-A 
formulation, the P-C formulation, and the J 
formulation and between the T-A formulation and 
the P-A formulation in terms of the disintegration 
time were noted.  
  
Dissolution test: The dissolution profiles for the 
Thai formulations (the T-A formulation, the T-B 
formulation, and the T-C formulation) are shown in 
Fig. 1-a. The T-B formulation was found to have a 
dissolution rate that was 15 slower than that of the 
T-A formulation. The dissolution profiles for the 
Filipino formulations (the P-A formulation, the P-B 
formulation, and the P-C formulation) are shown in 
Fig. 1-b. Differences in the dissolution profiles of 
the individual formulations were not noted.  
 
Dissolution profiles for all of the formulations are 
shown in Fig. 2. As is apparent, the T-A 
formulation, the T-B formulation, the T-C 
formulation, the P-A formulation, the P-C 
formulation, and the J formulation had dissolution 
of 85% or greater prior to 15 min. However, the P-
B formulation, did not have dissolution of 85% 
prior 15 min. All of the formulations were found to 
have dissolution of 85% or greater prior to 30. In 
addition, significant differences in dissolution at 15 
min were not noted for the P-B formulation in 
comparison to dissolution at 15 min for other 
formulations (p<0.05).  
 
Appearance: Diameters of individual formulations 
(long and short axes) are shown in Table 2. Thai 
formulations (the T-A formulation, the T-B 
formulation, and the T-C formulation) and the 
Japanese formulation were caplets. In contrast, 
Filipino formulations (the P-A formulation, the P-
B, and the P-C formulation) were all tablets.  
 
Oblong tablets had a long axis of 15.0–17.5 mm, a 
short axis of 7.0–8.0 mm, and a thickness of 5.5–
6.0 mm. Round tablets had a diameter of 12.8–13.0 
mm and a thickness of 3.7–4.5 mm. The name of 
the formulation was stamped on the surface of each 
tablet. The brand name was stamped on both sides 
of the T-A formulation. The T-B formulation and 
the T-C formulation had the specified content (500) 
and the brand name stamped on one side. The P-A 
formulation, the P-B formulation, and the P-C 
formulation had the specified content (500) and the 
brand name or the company logo stamped on one 
side (Fig. 3). In contrast, the J formulation only had 
an identification number stamped on one side. All 
of the P formulations were scored. A photo of the 
packaging of individual formulations is shown in 
Yutaka et al., World J Pharm Sci 2015; 3(6): 1031-1038 
1034 
 
Fig. 4. The T-A formulation, the T-B formulation, 
and the T-C formulation featured the brand name in 
Thai and English on the packaging. The P-A 
formulation, the P-B formulation, and the P-C 
formulation featured the brand name in English. 
The expiration date was listed on the packaging of 
the T formulations and the P formulations. The 
brand name in Japanese and English was written on 
the J formulation.  
 
DISCUSSION 
  
The purposes of this study were to compare quality 
standards for 7 seven AAP formulations available 
in Thailand, the Philippines, and Japan and to 
assess those standards. Comparison was done using 
physical and chemical parameters for AAP tablets 
(500 mg). Physical and chemical properties such as 
hardness, weight variation, content uniformity, 
dissolution, and preparation appearance (shape, 
stamping, and packaging) were compared. Tests 
yielded results specific to certain formulations. 
These results reflected differences in the physical 
properties of individual formulations.  
 
The weight variation test revealed differences in 
the weight of individual formulations. These results 
indicate differences in the amount and types of 
additives in individual formulations. The P-C 
formulation had a weight of 609.2±9.6 mg, and the 
standard deviation in that weight tended to be 
greater than that of other formulations.  
 
Hardness ranged from 70 N to 220 N. Differences 
in hardness were attributed to types of additives 
and tableting process used to produce individual 
formulations. A study has reported that a tablet 
with a diameter of 6–8 mm and a hardness of 50 N 
or greater or a tablet with a diameter of 9–10 mm 
and a hardness of 70 N or greater will typically not 
be damaged during manufacture or transport7. In 
addition, a high level of hardness causes the 
capping of tablets and can potentially cause tablet 
damage. The current findings indicated differences 
in the weight of individual formulations, and 
properties of additives in powder form, and tablet 
shape and size. However, tablets were presumably 
not hard enough to affect drug quality. A 
dissolution test is an important index with which to 
assess the pharmaceutical equivalence of tablets. 
Such an approach is used to compare brand-name 
and generic drugs. Japanese guidelines for generics 
stipulate 85% or more elution of AAP in 15 min. 
However, comparison of dissolution profiles 
indicated that the P-B formulation had elution of 
about 77% at 15 min, and this level of elution was 
lower than that from other formulations (p<0.05). 
The P-B formulation was found to have variations 
in weight and content. This means that its physical 
properties would differ from those of other 
formulations. Unlike the P-B formulation, the other 
6 formulations had around 85% or more elution of 
AAP in 15 min. Thus, these 6 formulations were 
generally equivalent. In contrast, the P-A 
formulation had a hardness of 215.9 N, which was 
greater than that of the other formulations. If tablets 
contain the same additives, their disintegration time 
is known to typically lag in proportion to their 
hardness 8. However, the dissolution profile for the 
P-A formulation was similar to that for the other 
Thai formulations (T), the Filipino formulations (P) 
(except for the P-B formulation), and the J 
formulation. Pharmaceutical information regarding 
the additives in individual formulations was 
unavailable, but based on the profiles for the 
formulations the additives in the P-A formulation 
contributed to the disintegration of those tablets. 
Looking specifically at hardness, the T-C 
formulation had a hardness of around 70 N, which 
was lower than that of the other formulations. This 
formulation is an OTC pharmaceutical that is 
available at convenience stores, so care with regard 
to damage is required when this formulation is 
commercially distributed. The T formulations and 
the P formulations featured the brand name or 
generic name on the surface of tablets/caplets. In 
Thailand, a prescription is not necessary when 
purchasing drugs in a convenience store, so drug 
packaging features a bar code. Depending on the 
country, there are differences in ways in which 
AAP formulations are handled despite the fact that 
those preparations contain AAP. 
 
This study conducted physical and chemical testing 
to compare different AAP formulations in 
accordance with the Japanese Pharmacopoeia. The 
tested formulations were the T-A formulation, the 
T-B formulation, and the T-C formulation that are 
sold in Thailand, the P-A formation and the P-B 
formulation that are sold in the Philippines, and the 
J formulation that is sold in Japan. These 
formulations were assumed to be equivalent. The 
Thai formulations and the Filipino formulations 
conformed to the US Pharmacopoeia while the J 
formulation was formulated based on the Japanese 
Pharmacopoeia. Assessing pharmaceutical 
equivalence or similarity is a crucial component in 
terms of harmonizing drugs in Thailand, the 
Philippines, and Japan, as the current results have 
indicated. In this study, adequate numbers of 
tablets of the T formulations and the P formulations 
could not be obtained to test tablet friability and 
perform a disintegration test and long-term stability 
test. Temperature and humidity levels vary more in 
Japan as seasons change (high temperatures and 
humidity in the summer and low temperatures and 
dryness in the winter) than they do in Thailand and 
the Philippines. A stability test that takes these 
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seasonal variations into account needs to be 
performed in the future.  
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Table 1 Tablets and caplets 
Country Brand Name  Serial  No. Lot No. 
Thailand  PARACAP T-A 140320 
Thailand  SaRa T-B 0140414 
Thailand  Tylenol T-C 401245 
Philippines  BIOGESTIC P-A 14038301 
Philippines  Rapidol P-B BC141M04 
Philippines PARASETAMOL P-C 9634 
Japan  CALONAL J 4041V 
 
Table 2 Comparison of the physical properties of each AAP formulation 
Serial No. T-A T-B T-C P-A P-B P-C J 
Content 
Uniformity (%) 
(n=10) 
102.1 
±1.0 
101.4 
±2.2 
97.1 
±3.6 
102.2 
±1.3 
101.7 
±2.5 
100.0 
±4.0 
100.4 
±1.6 
Weight Variation 
(mg) 
(n=10) 
564.0 
±2.8 
564.3 
±5.2 
629.7 
±1.7 
644.5 
±4.8 
549.8 
±8.4 
609.2 
±9.6 
559.4 
±0.7 
Hardness (N) 
(n=10) 
148.0 
±10.2 a 
137.0 
±13.2 b 
106.5 
±5.5 c 
215.9 
±11.6 d 
107.8 
±12.7 e 
71.5 
±10.6 f 
91.7 
±2.4 
Degradation (sec) 
(n=5)  
74.0 
±2.8 * 
128.5 
±19.9 
144.3 
±10.6 
192.2 
±11.7 
429.3 
±13.8 # 
121.8 
±22.9 
169.7 
±21.2 
Shape  
major-axis×minor-
axis 
×thick  
Couplet  
15.0×8.0 
×6.0 
Couplet 
17.5×7.0 
×5.5 
Couplet 
17.5×7.0 
×6.0 
Tablet 
12.8×4.3 
Tablet 
12.8×2.8 
Tablet 
13.0×4.5 
Couplet 
17.5×7.5 
×5.2 
a : p < 0.05 T-A vs. P-C, P-A, P-B, P-C, J ; b : p < 0.05 T-B vs. P-C, P-A, P-B, P-C, J 
c : p < 0.05 T-C vs. P-A, P-C, J ; d : p < 0.05 P-A vs. P-B, P-C, J 
e : p < 0.05 P-B vs. P-C, J ; f : p < 0.05 P-C vs. J 
# : p < 0.05 P-B vs. T-A, T-B, T-C, P-A, P-C, J ; * : p < 0.05 T-A vs. P-A  
Presented as mean ± SD. All statistical analyses were done using the Tukey-Kramer test 
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Figure 1 Dissolution profile of different AAP formulations 
(a) Thai formulations T-A, -B, and -C, (b) Filipino formulations P-A, -B, and -C, (c) Japanese formulation J 
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Figure 2 Dissolution profile of seven different AAP formulations 
# : p < 0.05 P-B vs. T-A, T-B, T-C, P-A, P-C, J 
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Figure 3 Appearance of formulations and stamping 
a) T-A, b) T-B, c) T-C, d) P-A, e) P-B, f) P-C, g) J 
 
a) b) c)
d) e) f) g)
 
 
Figure 4 Photograph of the blister pack 
a) T-A, b) T-B, c) T-C, d) P-A, e) P-B, f) P-C, g) J 
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